Breakthrough Results Unveiled: ASC40, a Novel FASN Inhibitor, Shows Promise in Treating Moderate Acne

ASC40, a groundbreaking fatty acid synthase (FASN) inhibitor, has recently made waves in the field of dermatology. Today, Ascletis Pharma announced the final results of a Phase II study on ASC40's efficacy in treating moderate acne at the 2024 American Academy of Dermatology (AAD) Annual Meeting held in San Diego. The study sheds light on the innovative mechanism of ASC40 and its potential as a game-changer in acne treatment.

The Study:

The Phase II trial (NCT05104125) was a randomized, double-blind, placebo-controlled, multicenter study involving 180 patients. Participants were administered ASC40 at doses of 25 mg, 50 mg, or 75 mg, or a placebo in a 1:1:1:1 ratio once daily for 12 weeks, followed by a 2-week follow-up period. The study aimed to assess the efficacy and safety of ASC40 compared to the placebo.

Mechanism of Action:

ASC40, also known as denifasirtide, is a potent and selective small-molecule inhibitor of fatty acid synthase (FASN). Its novel mechanism of action involves inhibiting de novo lipogenesis (DNL) in human sebocytes, thereby directly suppressing facial sebum production. Additionally, ASC40 reduces cytokine secretion, leading to anti-inflammatory effects. Previous clinical studies have shown significant reductions in facial sebum palmitic acid levels after just 10 days of ASC40 treatment.

Results:

Throughout the 12-week treatment period, improvements were observed across various efficacy endpoints, including total lesion count, inflammatory and non-inflammatory lesion count, treatment success rate, and Investigator's Global Assessment (IGA) score reduction of ≥2 from baseline. The 50 mg dose of ASC40 exhibited the most favorable results, with treatment success and IGA score reduction of ≥2 in 14.3% and 16.2% of patients, respectively. Median percentage (absolute) changes from baseline in total lesion count and inflammatory lesion count were -27.1% (-23.5) and -33.5% (-13) (p = 0.008 (0.030) and 0.003 (0.003)), respectively, after adjusting for the placebo.

Safety:

The incidence of treatment-related adverse events was comparable between ASC40 at doses of 25 mg (Grade 1 = 28.9%; Grade 2 = 20.0%), 50 mg (Grade 1 = 36.4%; Grade 2 = 11.4%), 75 mg (Grade 1 = 44.4%; Grade 2 = 17.8%), and the placebo (Grade 1 = 35.6%; Grade 2 = 13.3%). The most common treatment-related adverse event reported was dry eyes, with similar incidence rates observed across different doses of ASC40 and the placebo.

Based on the promising efficacy and safety data from this Phase II trial, a Phase III clinical trial evaluating the 12-week treatment with ASC40 at a daily dose of 50 mg has been initiated. Ascletis Pharma has obtained exclusive development, production, and commercialization rights for ASC40 in the Greater China region through a partnership with Sagimet Biosciences Inc.

In conclusion, ASC40, a first-in-class FASN inhibitor, has demonstrated its potential as an effective and safe treatment option for patients with moderate acne. These groundbreaking results pave the way for further research and development in the field of dermatology, offering hope for individuals struggling with this common skin condition.